Thursday, 15 October 2026European Markets

Euro Surges 14% Against Dollar as US Currency Hits 2022 Lows

The euro has gained 14% against the US dollar in 2025, while the British pound climbed 7%, as the greenback fell to its lowest level since 2022. The dollar's weakness stems from uncertainty ahead of Jerome Powell's June 2026 Federal Reserve departure and shifting investor sentiment toward European currencies.

Euro Surges 14% Against Dollar as US Currency Hits 2022 Lows
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro traded 14% higher against the US dollar in 2025, marking the greenback's steepest decline since 2022. The British pound gained 7% over the same period, reflecting a broad shift away from dollar-denominated assets.

Market uncertainty around the June 2026 Federal Reserve chair transition from Jerome Powell has weakened dollar confidence. Geopolitical developments, including progress on Iran-US nuclear negotiations, have accelerated the currency rotation.

European investors face new opportunities as dollar weakness makes US assets cheaper. American stocks, bonds, and real estate now cost 14% less in euro terms than at the start of 2025. European companies with US revenue streams see higher euro-equivalent earnings on repatriation.

The shift benefits European exporters to the United States. German manufacturers and French luxury brands gain pricing power as their products become more competitive against US-produced alternatives. Tourism sectors across Spain, Italy, and Greece expect increased American visitor spending.

Currency analysts warn the dollar's decline may reach limits soon. Jordan Rochester at Mizuho Bank forecasts potential GBP reversal below $1.30 as the UK Budget and Fed leadership change approach. Simon Phillips at No1 Currency noted pressure on sterling despite recent gains.

European bond markets have strengthened alongside currency gains. The euro's rise makes European government debt more attractive to international investors seeking alternatives to US Treasuries. UK gilt auctions drew record demand, with £69 billion in bids for £4.25 billion in inflation-linked bonds.

Strategic investors should consider US dollar exposure while valuations favor euro-based buyers. Technology stocks trading on US exchanges offer entry points 14% below year-start euro prices. Real estate investment trusts and corporate bonds present similar opportunities.

The currency shift also carries risks. A sudden dollar rebound would reduce gains on US holdings. European Central Bank policy decisions and eurozone economic data will determine whether the euro maintains its strength through year-end.

Market sentiment currently favors non-dollar currencies, but analysts caution against assuming permanent trends. Fed policy clarity following the 2026 chair transition could restore dollar demand.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com